COMPANY

NovoMedix

Keywords: small molecule oncology cancer fibrosis inflammatory diseases

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $356K (SBIR Phase I 1R43HL182659-01A1, new, notice Aug 24, 2026). NIH RePORTER 1R43HL182659-01A1 (Aug 24, 2026)
Evidence (1 event)
- Aug 24, 2026 · NIH RePORTER 1R43HL182659-01A1
  Organization: NOVOMEDIX, INC.; City/State: SAN DIEGO, CA; Project number: 1R43HL182659-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 355963; Administering IC: National Heart Lung and Blood Institute; Project title: Novel small molecule for the prevention and treatment of DMD cardiomyopathy; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Aug 24, 2026 Grant Government grant — SBIR: $355,963 (annual award, as published), announced Aug 24, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗
Sep 22, 2025 Grant Government grant — SBIR: $314,362 (annual award, as published), announced Sep 22, 2025. Agency: NIH/NIAMS. Source: government award database. source ↗
Sep 15, 2025 Grant Government grant — NIH N44: $2.98M (annual award, as published), announced Sep 15, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Last 2 years.

Aug 24, 2026 Government grant — SBIR: $355,963 (annual award, as published), announced Aug 24, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗
Sep 22, 2025 Government grant — SBIR: $314,362 (annual award, as published), announced Sep 22, 2025. Agency: NIH/NIAMS. Source: government award database. source ↗
Sep 15, 2025 Government grant — NIH N44: $2.98M (annual award, as published), announced Sep 15, 2025. Agency: NIH/NCI. Source: government award database. source ↗